NVAX Novavax Inc.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.

Fireside Chat details:
Date:Tuesday, March 9, 2021
Time:Available on-demand starting at 7:00 a.m. Eastern Time (ET)
Participants:Gregory M. Glenn, M.D., President, Research and Development and John Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit and connect with us on and .

Contacts:

Investors

Novavax, Inc.

Erika Schultz | 240-268-2022

Solebury Trout

Jennifer Porcelli | 617-974-8659

Media

Amy Speak | 617-420-2461

Laura Keenan | 410-419-5755



EN
08/03/2021

Underlying

NVAXNovavax Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novavax Inc.

Free Trial
NVAX NOVAVAX INC.

Novavax Inc: 1 director

A director at Novavax Inc sold/sold after exercising options 47,312 shares at 13.900USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

05/16/24 May 16, 2024 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences...

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion. Fireside Chat details:Date:Tuesday, March 9, 2021Time:Available on-demand starting at 7:00 a.m. Eastern Time (...

March 8, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results an...

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights 96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000 participants) in PREVENT-19 Phase 3 trialAgreements for ~300 million doses to dateAdditional 1.1 billion doses to be supplied to the COVAX Facility (jointly with Serum Institute of India)Clinical trial of variant strain vaccines as standalone and bivalent candidates expected mid-2021Company to host conference ca...

March 1, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Va...

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support local regulatory application GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Ta...

February 26, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal P...

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously po...

February 22, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch